Parthenon LLC Has $1.27 Million Holdings in Pfizer Inc. $PFE

Parthenon LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 47.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,780 shares of the biopharmaceutical company’s stock after selling 44,244 shares during the quarter. Parthenon LLC’s holdings in Pfizer were worth $1,268,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the third quarter worth approximately $29,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the second quarter worth approximately $30,000. Finally, True Wealth Design LLC increased its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PFE shares. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Scotiabank began coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Finally, UBS Group started coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Trading Down 1.7%

Shares of NYSE PFE opened at $25.65 on Monday. The stock has a market cap of $145.82 billion, a P/E ratio of 14.91 and a beta of 0.47. The firm has a 50 day moving average price of $25.40 and a two-hundred day moving average price of $25.00. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.